Back

MZF1-mediated GAPDH overexpression drives glycolytic reprogramming and neuroendocrine progression in advanced prostate cancer

Liu, W.; He, L.; Zhong, C.; Wang, Y.; zhang, d.; Mirza, M.; Li, B.

2026-06-08 cancer biology
10.64898/2026.06.03.729867 bioRxiv
Show abstract

Drug resistance to the androgen receptor (AR) antagonist is a critical obstacle in the clinic for advanced prostate cancers. Especially, AR antagonist treatment-induced neuroendocrine progression represents a lethal and therapy-resistant subtype. Although transcriptional and epigenetic lineage plasticity have been extensively implicated in treatment-induced neuroendocrine progression, the contribution of metabolic adaptation remains incompletely understood. Here, we identified a previously unrecognized metabolic reprogramming mechanism induced by AR antagonists in castration-resistant prostate cancer (CRPC) models. AR antagonist treatment markedly enhanced glycolytic activity and induced glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. Genetic depletion of GAPDH suppressed AR antagonist-induced glycolytic activation, altered transcriptomic and metabolic programs, reduced neuroendocrine-associated marker expression, and inhibited xenograft tumor growth. Mechanistically, GAPDH promoter pulldown coupled with mass spectrometry, siRNA screening, and chromatin immunoprecipitation assays identified myeloid zinc finger-1 (MZF1) as a key transcription factor for Enzalutamide-induced GAPDH gene expression. Pharmacological inhibition of GAPDH using koningic acid (KA) or penta-O-galloyl-{beta}-D-glucopyranose (PGG) significantly suppressed tumor growth and attenuated neuroendocrine-associated molecular programs in CRPC cell-derived xenograft and patient-derived t-NEPC xenograft models. Collectively, our findings identify an AR antagonist-induced MZF1-GAPDH signaling axis that promotes glycolytic activation and neuroendocrine-associated metabolic adaptation during treatment resistance. These results support targeting GAPDH-dependent metabolic reprogramming as a potential therapeutic strategy for treatment-resistant prostate cancer. Graphic abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=112 SRC="FIGDIR/small/729867v1_ufig1.gif" ALT="Figure 1"> View larger version (58K): org.highwire.dtl.DTLVardef@180c5feorg.highwire.dtl.DTLVardef@146c015org.highwire.dtl.DTLVardef@1ece2f4org.highwire.dtl.DTLVardef@12819c0_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
eLife
5422 papers in training set
Top 8%
8.4%
2
Cell Reports
1338 papers in training set
Top 5%
7.1%
3
Oncogene
76 papers in training set
Top 0.2%
6.3%
4
Journal of Clinical Investigation
164 papers in training set
Top 0.5%
4.8%
5
Nature Communications
4913 papers in training set
Top 36%
4.3%
6
Cell Chemical Biology
81 papers in training set
Top 0.7%
3.6%
7
Molecular Cancer Therapeutics
33 papers in training set
Top 0.2%
3.6%
8
Cancer Research Communications
46 papers in training set
Top 0.2%
3.1%
9
Clinical Cancer Research
58 papers in training set
Top 0.6%
3.1%
10
Frontiers in Oncology
95 papers in training set
Top 1%
3.1%
11
Cell Reports Medicine
140 papers in training set
Top 2%
2.7%
50% of probability mass above
12
Cancer Research
116 papers in training set
Top 1%
2.4%
13
JCI Insight
241 papers in training set
Top 2%
2.4%
14
iScience
1063 papers in training set
Top 10%
2.1%
15
Cancer Cell
38 papers in training set
Top 0.8%
2.1%
16
Genome Medicine
154 papers in training set
Top 4%
2.1%
17
Neoplasia
22 papers in training set
Top 0.2%
1.7%
18
Journal of Translational Medicine
46 papers in training set
Top 1.0%
1.7%
19
Advanced Science
249 papers in training set
Top 12%
1.7%
20
British Journal of Cancer
42 papers in training set
Top 0.9%
1.7%
21
Cancers
200 papers in training set
Top 3%
1.3%
22
Gastroenterology
40 papers in training set
Top 1%
1.2%
23
The Prostate
11 papers in training set
Top 0.1%
0.9%
24
Molecular Cancer Research
42 papers in training set
Top 0.6%
0.9%
25
Theranostics
33 papers in training set
Top 1%
0.9%
26
Science Advances
1098 papers in training set
Top 28%
0.8%
27
Journal of Biological Chemistry
641 papers in training set
Top 4%
0.8%
28
PLOS ONE
4510 papers in training set
Top 67%
0.7%
29
Molecular & Cellular Proteomics
158 papers in training set
Top 2%
0.7%
30
Communications Biology
886 papers in training set
Top 26%
0.7%